Newron Pharmaceuticals S.p.A. (ETR:NP5)

Market Cap	219.12M
Revenue (ttm)	6.97M
Net Income (ttm)	-18.83M
Shares Out	n/a
EPS (ttm)	-1.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,783
Average Volume	4,746
Open	11.22
Previous Close	11.00
Day's Range	10.98 - 11.22
52-Week Range	6.90 - 11.90
Beta	0.66
RSI	60.16
Earnings Date	Apr 1, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schiz...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NP5

Financial Performance

In 2023, Newron Pharmaceuticals's revenue was 9.06 million, an increase of 48.62% compared to the previous year's 6.09 million. Losses were -16.22 million, -7.25% less than in 2022.